Study of BLU-808 in Allergic Rhinoconjunctivitis

Launched by BLUEPRINT MEDICINES CORPORATION · Apr 3, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called BLU-808 for people who suffer from allergic rhinoconjunctivitis (ARC), which is a condition caused by allergies to ragweed pollen. The trial aims to assess how safe the treatment is, how well it works, and how the body processes it. Participants will be exposed to ragweed pollen in a controlled environment to evaluate their symptoms and responses.

To be eligible for the study, participants must be adults aged 18 or older with a history of ragweed-induced ARC for at least two years and must have tested positive for ragweed allergies recently. They need to be in good health overall and should not be taking other allergy medications or have other serious health conditions that could affect the study results. If you decide to participate, you'll be closely monitored throughout the trial, and you'll have the opportunity to contribute to research that could help others with similar allergies in the future.

Gender

ALL

Eligibility criteria

• • Key Inclusion Criteria
• • 1. Adults, 18 years of age or older, willing to provide written informed consent, and willing to comply with all study requirements.
• • 2. History (\>2 years) of ragweed-induced ARC.
• • 3. A positive ragweed skin prick test (mean diameter of ≥ 5 mm) in the last 6 months.
• • 4. Must meet clinically relevant nasal and ocular symptoms as defined by the protocol.
• • Key Exclusion Criteria
• Participants are excluded from the study if any of the following criteria are met:
• • 1. Receiving medications (oral, nasal, topical, ocular, or injectable) to treat their ragweed or other allergy symptoms and/or receiving any medications that impact participants' safety or interfere with study assessments or interpretation of study results.
• • 2. Have active rhinitis, sinusitis, and/or other severe allergies not associated with the ragweed pollen that may interfere with study symptom assessments.
• • 3. Any prior or ongoing clinically significant illness, medical or psychiatric condition, surgical history, or physical finding that may interfere with the assessment or interpretation of study results.
• • 4. Clinically significant moderate to severe, uncontrolled cardiovascular, renal or hepatic disease.
• • 5. Significant bleeding risk or coagulation disorders.
• • 6. Any form of smoking, vaping or history of alcohol and drug abuse.
• • 7. Any malignancy within the past 5 years prior to Screening/AEC 1, except for basal cell or squamous cell carcinomas of the skin or carcinoma in situ.
• • 8. Inadequately controlled asthma that could affect the safety of the participant or interfere with the assessment or interpretation of study results.
• • 9. Known active/latent infection (viral, bacterial, fungal, helminth, or mycobacterial) such as tuberculosis, hepatitis B, hepatitis C, AIDS-related illness, or COVID-19 infection.
• • 10. History of sinonasal conditions that may confound the assessment or interpretation of study results.